Phanchaporn Wongmaneerung

Dr. Phanchaporn Wongmaneerung

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
ICImjai Chitapanarux
Imjai Chitapanarux
PSPatumrat Sripan
Patumrat Sripan
ASAreewan Somwangprasert
Areewan Somwangprasert
CCChaiyut Charoentum
Chaiyut Charoentum
WOWimrak Onchan
Wimrak Onchan
LHLalita Huntrakul
Lalita Huntrakul
Objective: This study was attempted to investigate overall survival by stage at diagnosis in female breast cancerpatients in Northern Thailand by using 2 different staging systems; namely, American Joint Committee on Cancer (AJCC)Tumor (T), Nodal (N) and Metastatic (M) staging system and Surveillance Epidemiology and End Results (SEER)summary staging system. Methods: We studies female breast cancer patients whose data were registered in Chiang Maicancer registries between January 2006 and December 2015. Data were recorded in SEER summary staging system.The TNM AJCC staging was searched in the medical records. Results: A total of 3,873 female breast cancer patientswere diagnosed from 2006-2015. All data sets were recorded in SEER summary stage 2000. Early stage was the mostprevalent stage at the time of diagnosis (58%), followed by loco-regional advanced stage (32%), and metastatic breastcancer (10%). The 5-year overall survival rate of early, loco-regional advanced, and metastatic stages were 85.3%,66.4%, and 26.2%, respectively. After examining the medical records, we excluded patients who had no data on T, N,and M in their records. Finally, only 3,251 patients were analyzed for AJCC stage-specific survival. The 5-year overallsurvival rate in stages I, II, III, and IV were 94.4%, 85.0%, 56.6%, and 28.3%, respectively. Conclusion: Comparingto more stable economic countries, the 5-year overall survival rate for a specific stage of breast cancer in NorthernThailand was slightly lower in early stage and stage I-II in accordance with AJCC, but much lower in loco-regional stageand stage III with respect to AJCC. Nevertheless, it was similar in metastatic stage and stage IV according to AJCC.

20 July 2023 in Scientifica
Verified
Journal Article
Open access
PDF file
JRJETSADA RUANGSURIYA
JETSADA RUANGSURIYA
JSJirapast Sichaem
Jirapast Sichaem
Apichat TantraworasinApichat Tantraworasin
Apichat Tantraworasin
SSSomcharoen Saeteng
Somcharoen Saeteng
PWPhanchaporn Wongmaneerung
Phanchaporn Wongmaneerung
KIKewalin Inthanon
Kewalin Inthanon
Reactive oxygen species (ROS) contribute to cancer growth and metastasis. Using antioxidants to modulate cellular ROS levels is a promisingstrategy for cancer prevention and treatment. Calophyllum inophyllum L., or tamanu, is a medicinal plant renowned for its anti-inflammatory, antioxidant, and anticancer properties in traditional medicine systems. However, the anticancer effects of C. inophyllum extract on cellular ROS remain unexplored. This study represents the first report on such effects and provides the potential mechanisms underlying the anticancer properties of C. inophyllum extract. The branches of C. inophyllum were extracted, and the extract was comprehensively analyzed for phytochemical constituents, antioxidant capacity, total phenolic content, and total flavonoid content. Subsequently, the extracts potential anticancer properties were evaluated using patient-derived cells from breast and lung cancer. The results revealed that the C. inophyllum extract possesses notable antioxidant activity and demonstrated no cytotoxicity within the initial 24h of treatment. However, after 72h, it exhibited significant antiproliferative effects. Moreover, the extract exhibited inhibitory properties against migration and invasion at concentrations below the IC50, which corresponded to the expression of related genes. Notably, these effects correlated with the reduction of intracellular ROS levels. Overall, our findings highlight the anticancer potential of C. inophyllum extract, emphasize its ability to modulate cellular ROS levels and target key molecular pathways involved in cancer progression. This study sheds light on the promising therapeutic implications of C. inophyllum extract as a novel agent for cancer treatment, which is safe for normal cells.

9 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CDChularat Duangkaew
Chularat Duangkaew
ASAreewan Somwangprasert
Areewan Somwangprasert
KWKirati Watcharachan
Kirati Watcharachan
PWPhanchaporn Wongmaneerung
Phanchaporn Wongmaneerung
WKWasana Ko-iam
Wasana Ko-iam
CDChagkrit Ditsatham
Chagkrit Ditsatham
Purpose: To compare the survival outcomes of early-stage breast cancer patients treated with breast-conserving therapy (BCT) and mastectomy. Method: This retrospective study includes 1330 early-stage breast cancer patients treated at Chiang Mai University (CMU) hospital, using data from the Chiang Mai Cancer Registry between 2004 and 2015. Information pertinent to patients and their treatment was collected for analysis. Time-to-event analysis was performed using Kaplan–Meier methods. Results: The baseline characteristics of 1330 patients showed significant differences between the BCT and mastectomy groups in terms of age, tumor size, and tumor location. BCT patients were younger, had smaller tumors, and exhibited less nodal involvement. Propensity score matching created a balanced cohort of 534 patients where differences persisted in age and tumor size. Univariate analysis revealed significant survival associations for BCT, younger age, and smaller tumor size. Multivariate analysis confirmed these factors, with BCT showing an adjusted hazard ratio (HR) of 0.58 (95% CI: 0.36–0.93; p = 0.023) compared to mastectomy. Kaplan–Meier survival analysis demonstrated a significant survival advantage for BCT, particularly in HER2-enriched and triple-negative subtypes. The 15-year overall survival was 80.01% in the BCT group versus 64.33% in the mastectomy group (p < 0.001). Conclusions: This study reveals key differences between outcomes following breast-conserving therapy (BCT) and mastectomy patients, including age and tumor characteristics. BCT showed improved overall survival, particularly in HER2-enriched and triple-negative breast cancers. However, our study’s limitations may affect the results. These findings suggest that BCT may offer survival benefits for specific subtypes, highlighting the importance of personalized treatment approaches.